FindTrial
Sign In

PHE885

BIOLOGICAL4 trials

Sponsors

Novartis Pharma AG, Novartis Pharma Services AG, Novartis Pharmaceuticals

Conditions

Adult patients with relapsed and refractory multiple myelomaAll patients who have been treated with Novartis or Penn CAR-T for any indicationMultiple Myeloma

Phase 1

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
TerminatedNCT04318327
Novartis PharmaceuticalsMultiple Myeloma
Start: 2020-07-23End: 2025-04-29Updated: 2026-04-01

Phase 2

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
TerminatedNCT05172596
Novartis PharmaceuticalsMultiple Myeloma
Start: 2022-03-03End: 2025-05-21Updated: 2026-01-13
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
CompletedCTIS2023-507140-37-00
Novartis Pharma AGAdult patients with relapsed and refractory multiple myeloma
Start: 2022-06-22End: 2025-05-19Target: 61Updated: 2025-01-27

Phase 3

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-CellTherapy
RecruitingCTIS2023-508128-37-00
Novartis Pharma Services AGAll patients who have been treated with Novartis or Penn CAR-T for any indication
Start: 2017-07-19Target: 180Updated: 2025-10-22

Related Papers

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM
Blood2025-11-03
Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform
Blood2024-11-051 citations
T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity
Blood2023-11-025 citations
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Journal of Clinical Oncology2023-06-0134 citations
P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
HemaSphere2022-06-016 citations
PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
HemaSphere2022-06-012 citations
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform
Blood2021-11-0522 citations
Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma
Blood2021-11-059 citations